Market research
PLSE Pulse Biosciences Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 4B
- P/E ratio
- Not available
- Analyst target
- 45.25
- Dividend yield
- Not available
- Beta
- 1.58
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- ISIN
- US74587B1017
- Market cap
- 4B
- P/E ratio
- Not available
- Analyst target
- 45.25
- Dividend yield
- Not available
- Beta
- 1.58
About
About Pulse Biosciences Inc
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers nPulse System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; nPulse Vybrance Percutaneous Electrode system for soft tissue ablation in surgical setting; nPulse Cardiac Surgical Clamp designed for use in surgical treatment of atrial fibrillation (AF); nPulse Cardiac Catheter System designed to provide a circumferential, or circular, ablation in a single treatment cycle; and nPulse Console, a software-enabled console-based platform designed to accommodate the clinical workflow preferred by physicians. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Miami, Florida.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the PLSE discussion.
5 years, 4 months ago
Pulse Biosciences, Inc is currently in a long term downtrend where the price is trading 18.1% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Pulse Biosciences, Inc's total revenue rose by inf% to $114K since the same quarter in the previous year.
Its net income has increased by 0.3% to $-14M since the same quarter in the previous year.
Finally, its free cash flow grew by 2.8% to $-10M since the same quarter in the previous year.
Based on the above factors, Pulse Biosciences, Inc gets an overall score of 4/5.